Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2905 USD | -2.19% | -8.65% | -47.18% |
Business Summary
Number of employees: 4
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Poirier
CEO | Chief Executive Officer | 68 | 19-12-31 |
Christopher Lotz
DFI | Director of Finance/CFO | 59 | 01-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kurt Kruger
BRD | Director/Board Member | 68 | 19-12-31 |
Sidney Emery
BRD | Director/Board Member | 74 | 20-12-06 |
Michael Poirier
CEO | Chief Executive Officer | 68 | 19-12-31 |
Ira Ritter
BRD | Director/Board Member | 75 | 07-12-31 |
Director/Board Member | 49 | 19-12-31 | |
Richard David
BRD | Director/Board Member | 64 | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,307,371 | 5,580,883 ( 88.48 %) | 0 | 88.48 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.18% | 1.83M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- QLGN Stock
- Company Qualigen Therapeutics, Inc.